
- /
- Supported exchanges
- / US
- / CRVS.NASDAQ
Corvus Pharmaceuticals Inc (CRVS NASDAQ) stock market data APIs
Corvus Pharmaceuticals Inc Financial Data Overview
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell atopic dermatitis, asthma, psoriasis, and fibrotic diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Corvus Pharmaceuticals Inc data using free add-ons & libraries
Get Corvus Pharmaceuticals Inc Fundamental Data
Corvus Pharmaceuticals Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -31 133 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-06-13
- EPS/Forecast: -0.12
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Corvus Pharmaceuticals Inc News

Corvus Q1 2025 presentation: Phase 1 atopic dermatitis data drives stock surge
Introduction & Market Context Corvus Pharmaceuticals (NASDAQ:CRVS) presented its first quarter 2025 business update on May 8, highlighting promising clinical data for its lead drug candidate soquelit...


Tuesday's Insider Activity: Major Buys and Sells Shake Up Markets
This article summarizes the top insider buys and sells reported on Tuesday, July 1, 2025, for US stocks. Top Insider Buys: Kymera Therapeutics Inc (NASDAQ:KYMR): A group of directors, including Mar...

OrbiMed Advisors sells Corvus Pharma (CRVS) shares worth $4.89 million
OrbiMed Advisors LLC, a major shareholder in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), sold 1,176,332 shares of common stock on June 27, 2025, for approximately $4.89 million. The shares were sold a...

Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Cohort 3 demonstrates earlier and deeper responses compared to cohorts 1-2 All three cohorts show separation from placebo with statistically significant difference from placebo at day 28 Cohort 3 de...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.